Friday 16 October 2026
Export CUE’s income statement to Excel — free account
Cue Biopharma, Inc.
Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024. In the quarter to June 2026, revenue grew 166.7%, EPS fell 793.2% and free cash flow fell 742.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
16.96
1.71
−9.16%
Follow CUE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 3 | 2 | 3 | 3 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
1.05 | 6.60 | 23.15 | 76.09 | 23.66 | 113.66 | 101.08 | 0.00 | — | — |
Altman Z-Score |
(11.88) | (15.90) | (5.93) | (2.51) | 7.78 | 7.67 | 9.38 | 0.88 | — | — |
Altman Z″-Score (non-manufacturers) |
(27.27) | (39.70) | (16.40) | (5.45) | (3.02) | 0.65 | (0.50) | (2.79) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
(26.83) | (6.79) | (11.60) | (9.01) | (33.21) | (51.22) | (54.30) | (24.25) | — | — |
Beneish M-Score |
(0.40) | (3.00) | 5.00 | (6.36) | 0.36 | (2.31) | — | — | — | — |
P/B ratio |
1.09 | 3.51 | 3.43 | 1.44 | 5.40 | 4.54 | 6.40 | 2.78 | — | — |
Price to Tangible BV |
1.10 | 3.54 | 3.44 | 1.45 | 5.41 | 4.55 | 6.42 | 2.80 | — | — |
EV/Sales |
0.08 | 4.70 | 15.74 | 22.84 | 20.02 | 89.02 | 85.58 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(0.11) | (1.20) | (2.16) | (0.68) | (7.70) | (8.64) | (9.61) | (2.09) | — | — |
EV/FCF |
(0.10) | (1.20) | (2.16) | (0.68) | (7.53) | (8.48) | (9.64) | (1.96) | — | — |
Quick Ratio |
2.50 | 1.78 | 2.96 | 6.61 | 5.28 | 5.29 | 5.16 | 6.32 | 11.93 | 14.03 |
Current Ratio |
2.74 | 1.84 | 3.01 | 6.68 | 5.35 | 5.36 | 5.24 | 6.53 | 12.17 | 14.18 |
Net Debt/EBITDA |
1.10 | 0.46 | 0.78 | 1.26 | 1.28 | 1.77 | 1.49 | 1.04 | 2.80 | 2.01 |
Debt/Assets |
0.00% | 13.46% | 13.27% | 10.95% | 12.05% | 7.18% | 8.09% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.25 | 0.22 | 0.15 | 0.15 | 0.09 | 0.11 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.74 | 0.20 | 0.07 | 0.01 | 0.16 | 0.04 | 0.06 | 0.02 | 0.00 | 0.00 |
Operating CF/Net income |
0.82 | 0.89 | 0.79 | 0.79 | 0.88 | 0.73 | 0.84 | 0.68 | 0.52 | 0.78 |
Capex/Depreciation |
(0.17) | 0.07 | 0.01 | (0.26) | (0.71) | (0.52) | 0.11 | (2.44) | (2.87) | (2.55) |
Interest Coverage |
(74.38) | (52.14) | (41.89) | (74.65) | (1,798.85) | (82.80) | (87.82) | (102.92) | — | (76,583.00) |
| (121.11%) | (149.03%) | (98.73%) | (80.82%) | (61.16%) | (67.10%) | (82.88%) | (81.57%) | (60.52%) | (69.27%) | |
| (71.51%) | (86.80%) | (66.40%) | (60.69%) | (48.28%) | (52.34%) | (62.75%) | (69.41%) | (55.83%) | (64.92%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (244.49%) | (2,367.67%) | (2,369.89%) | 0.00% | 0.00% | (2,408.88%) |
Return on Tangible Assets |
(112.10%) | (341.22%) | (144.26%) | (78.96%) | (76.41%) | (61.08%) | (71.65%) | (104.86%) | (37.83%) | (50.74%) |
Average Days of Receivables |
73.70 | 37.14 | 112.89 | 16.71 | 76.77 | 164.03 | 79.67 | 0.00 | — | — |
Research and Development Expense of Revenue |
137.42% | 390.82% | 743.21% | 3,098.63% | 276.73% | 1,063.49% | 794.83% | 2,498.17% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
59.14% | 157.05% | 303.83% | 1,298.71% | 115.83% | 464.48% | 368.39% | 988.55% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
17.27% | 73.72% | 149.00% | 762.73% | 77.07% | 332.27% | 188.56% | 627.84% | 0.00% | 0.00% |
Graham Net Nets |
0.73 | 0.17 | 0.21 | 0.54 | 0.14 | 0.19 | 0.13 | 0.31 | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
(105.02%) | (68.88%) | (39.61%) | (56.07%) | (12.48%) | (12.56%) | (10.59%) | (41.10%) | — | — |
Free Cash Flow Yield |
(75.61%) | (59.18%) | (31.45%) | (44.31%) | (11.24%) | (9.23%) | (8.79%) | (29.90%) | — | — |
Revenue per Share |
8.71 | 4.95 | 3.60 | 1.05 | 14.34 | 3.30 | 4.71 | 1.70 | 0.00 | 0.00 |
Operating CF per Share |
(6.87) | (19.37) | (26.23) | (35.22) | (37.28) | (34.01) | (41.96) | (39.39) | (33.97) | (24.11) |
Capex per Share |
(0.04) | 0.02 | 0.00 | (0.14) | (0.86) | (0.62) | 0.11 | (2.77) | (3.37) | (2.08) |
Free Cash Flow per Share |
(6.92) | (19.35) | (26.23) | (35.36) | (38.13) | (34.64) | (41.85) | (42.16) | (37.34) | (26.20) |
Cash per Share |
8.95 | 12.47 | 32.03 | 64.27 | 61.79 | 88.84 | 80.94 | 58.56 | 178.54 | 60.51 |
Shareholders Equity per Share |
8.38 | 9.33 | 24.34 | 55.33 | 62.86 | 82.60 | 74.37 | 50.67 | 172.38 | 61.31 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
8.38 | 9.33 | 24.34 | 55.33 | 62.86 | 82.60 | 74.37 | 50.67 | 172.38 | 61.31 |
Free Cash Flow |
(21.82) | (36.30) | (39.96) | (41.97) | (39.73) | (33.09) | (30.72) | (28.27) | (13.35) | (6.48) |
Working Capital |
23.49 | 11.45 | 34.37 | 65.64 | 55.68 | 71.21 | 49.37 | 34.39 | 59.72 | 14.07 |
Capital Expenditures |
(0.14) | 0.03 | 0.00 | (0.16) | (0.89) | (0.60) | 0.08 | (1.85) | (1.20) | (0.52) |
Net Current Asset Value |
21.20 | 10.45 | 27.01 | 51.59 | 50.56 | 66.91 | 44.00 | 29.22 | 59.72 | 14.03 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.13 | 0.06 | 0.19 | (0.02) | 1.62 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.25 | 0.92 | 0.45 | 0.42 | 0.59 | 0.54 | 0.40 | 0.27 | 0.25 | 0.20 |
Cash ROIC |
(39.93%) | (80.27%) | (42.49%) | (27.62%) | (28.39%) | (19.36%) | (25.64%) | (38.60%) | (10.64%) | (21.51%) |
Accounts Receivable Turnover |
8.46 | 7.03 | 6.26 | 0.78 | 6.55 | 2.90 | 3.18 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 |
Average Receivables |
3.25 | 1.32 | 0.88 | 1.60 | 2.28 | 1.09 | 1.09 | — | — | — |
Average Payables |
3.39 | 3.16 | 3.12 | 2.66 | 2.33 | 1.48 | 1.46 | 1.85 | 1.10 | 0.36 |
Average Assets |
37.20 | 46.86 | 76.41 | 87.34 | 91.47 | 85.57 | 58.48 | 56.16 | 41.62 | 11.80 |
Average Common Equity |
21.97 | 27.29 | 51.38 | 65.59 | 72.20 | 66.75 | 44.28 | 47.79 | 38.39 | 11.06 |
Columns are period end dates